Predictive risk factors of phenoconversion in idiopathic REM sleep behavior disorder: the Italian study "FARPRESTO"

Monica Puligheddu, Michela Figorilli, Elena Antelmi, Dario Arnaldi, Elisa Casaglia, Ernesto d'Aloja, Luigi Ferini-Strambi, Raffaele Ferri, Gian Luigi Gigli, Francesca Ingravallo, Michelangelo Maestri, Michele Terzaghi, Giuseppe Plazzi, and the FARPRESTO Consortium, Monica Puligheddu, Michela Figorilli, Elena Antelmi, Dario Arnaldi, Elisa Casaglia, Ernesto d'Aloja, Luigi Ferini-Strambi, Raffaele Ferri, Gian Luigi Gigli, Francesca Ingravallo, Michelangelo Maestri, Michele Terzaghi, Giuseppe Plazzi, and the FARPRESTO Consortium

Abstract

Most patients with idiopathic REM sleep behavior disorder (iRBD) will develop an overt α-synucleinopathy over time, with a rate of phenoconversion of 73.5% after 12 years from diagnosis. Several markers of phenoconversion were identified; however, most studies investigated biomarkers separately, with retrospective study designs, in small cohorts or without standardized data collection methods. The risk FActoRs PREdictive of phenoconversion in idiopathic REM sleep behavior disorder: the Italian STudy (FARPRESTO) is a multicentric longitudinal retrospective and prospective study with a cohort of incident (prospective recruitment) and prevalent (retrospective recruitment) iRBD patients, whose primary aim is to stratify the risk of phenoconversion, through the systematic collection by means of electronic case report forms of different biomarkers. Secondary aims are to (1) describe the sociodemographic and clinical characteristics of patients with iRBD; (2) collect longitudinal data about the development of α-synucleinopathies; (3) monitor the impact of iRBD on quality of life and sleep quality; (4) assess the correlation between phenoconversion, cognitive performance, and loss of normal muscle atony during REM sleep; (5) identify RBD phenotypes through evaluating clinical, biological, neurophysiological, neuropsychological, and imaging biomarkers; and (6) validate vPSG criteria for RBD diagnosis. The FARPRESTO study will collect a large and harmonized dataset, assessing the role of different biomarkers providing a unique opportunity for a holistic, multidimensional, and personalized approach to iRBD, with several possible application and impact at different levels, from basic to clinical research, and from prevention to management. The FARPRESTO has been registered at clinicaltrials.gov (NCT05262543).

Keywords: Biomarkers; Neurodegeneration; Parkinson; RBD; REM sleep behavior disorder.

Conflict of interest statement

None.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
FARPRESTO study design. FARPRESTO study design flowchart (Source clipart: clipart-library.com)

References

    1. American Academy of Sleep Medicine . International classification of sleep disorders. Darien: American Acad. of Sleep Medicine; 2014.
    1. Fantini ML, Corona A, Clerici S, Ferini-Strambi L. Aggressive dream content without daytime aggressiveness in REM sleep behavior disorder. Neurology. 2005;65:1010–1015. doi: 10.1212/01.wnl.0000179346.39655.e0.
    1. Oudiette D, De Cock VC, Lavault S, Leu S, Vidailhet M, Arnulf I. Nonviolent elaborate behaviors may also occur in REM sleep behavior disorder. Neurology. 2009;72:551–557. doi: 10.1212/01.wnl.0000341936.78678.3a.
    1. Cesari M, Heidbreder A, St. Louis EK, Sixel-Döring F, Bliwise DL, Baldelli L, et al. Video-polysomnography procedures for diagnosis of rapid eye movement sleep behavior disorder (RBD) and the identification of its prodromal stages: guidelines from the International RBD Study Group. Sleep. 2022;45:zsa257. doi: 10.1093/sleep/zsab257.
    1. McCarter SJ, St. Louis EK, Duwell EJ, Timm PC, Sandness DJ, Boeve BF, et al. Diagnostic thresholds for quantitative REM sleep phasic burst duration, phasic and tonic muscle activity, and REM atonia index in REM sleep behavior disorder with and without comorbid obstructive sleep apnea. Sleep. 2014;37:1649–62. doi: 10.5665/sleep.4074.
    1. Frauscher B, Iranzo A, Gaig C, Gschliesser V, Guaita M, Raffelseder V, et al. Normative EMG values during REM sleep for the diagnosis of REM sleep behavior disorder. Sleep. 2012;35:835–847. doi: 10.5665/sleep.1886.
    1. Montplaisir J, Gagnon J-F, Fantini ML, Postuma RB, Dauvilliers Y, Desautels A, et al. Polysomnographic diagnosis of idiopathic REM sleep behavior disorder. Mov Disord. 2010;25:2044–2051. doi: 10.1002/mds.23257.
    1. Ferri R, Manconi M, Plazzi G, Bruni O, Vandi S, Montagna P, et al. A quantitative statistical analysis of the submentalis muscle EMG amplitude during sleep in normal controls and patients with REM sleep behavior disorder. J Sleep Res. 2008;17:89–100. doi: 10.1111/j.1365-2869.2008.00631.x.
    1. Ferri R, Rundo F, Manconi M, Plazzi G, Bruni O, Oldani A, et al. Improved computation of the atonia index in normal controls and patients with REM sleep behavior disorder. Sleep Med. 2010;11:947–949. doi: 10.1016/j.sleep.2010.06.003.
    1. Cicero CE, Giuliano L, Luna J, Zappia M, Preux P-M, Nicoletti A. Prevalence of idiopathic REM behavior disorder: a systematic review and meta-analysis. Sleep. 2021;44:zsaa294. doi: 10.1093/sleep/zsaa294.
    1. Postuma RB, Iranzo A, Hu M, Högl B, Boeve BF, Manni R, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain. 2019;142:744–759. doi: 10.1093/brain/awz030.
    1. Arnaldi D, Chincarini A, Hu MT, Sonka K, Boeve B, Miyamoto T, Puligheddu M, De Cock VC, Terzaghi M, Plazzi G, Tachibana N, Morbelli S, Rolinski M, Dusek P, Lowe V, Miyamoto M, Figorilli M, Verbizier D, Bossert I, Antelmi E, … Nobili F (2021) Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder. Brain : a journal of neurology 144(1):278–287
    1. Zhang H, Iranzo A, Högl B, Arnulf I, Ferini-Strambi L, Manni R, Miyamoto T, Oertel WH, Dauvilliers Y, Ju YE, Puligheddu M, Sonka K, Pelletier A, Montplaisir JY, Stefani A, Ibrahim A, Frauscher B, Leu-Semenescu S, Zucconi M, Terzaghi M, … Postuma RB (2022) Risk Factors for phenoconversion in rapid eye movement sleep behavior disorder. Ann Neurol 91(3):404–416
    1. Postuma RB. Prodromal Parkinson’s disease—using REM sleep behavior disorder as a window. Parkinsonism Relat Disord. 2014;20:S1–4. doi: 10.1016/S1353-8020(13)00400-8.
    1. Postuma RB, Gagnon J-F, Bertrand J-A, Génier Marchand D, Montplaisir JY. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology. 2015;84:1104–1113. doi: 10.1212/WNL.0000000000001364.
    1. Postuma RB, Iranzo A, Hogl B, Arnulf I, Ferini-Strambi L, Manni R, et al. Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: a multicenter study: risk factors in RBD. Ann Neurol. 2015;77:830–839. doi: 10.1002/ana.24385.
    1. Terzaghi M, Toscano G, Casoni F, Picascia M, Arnaldi D, Rustioni V, Versino M, Sinforiani E, Manni R (2019) Assessment of cognitive profile as a prodromal marker of the evolution of rapid eye movement sleep behavior disorder. Sleep 42(8):zsz103
    1. Miglis MG, Adler CH, Antelmi E, Arnaldi D, Baldelli L, Boeve BF, et al. Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder. Lancet Neurol. 2021;20:671–684. doi: 10.1016/S1474-4422(21)00176-9.
    1. Dauvilliers Y. Identifying the best biomarkers for α-synucleinopathies. Lancet Neurol. 2021;20:593–594. doi: 10.1016/S1474-4422(21)00201-5.
    1. Feigl B, Dumpala S, Kerr GK, Zele AJ. Melanopsin cell dysfunction is involved in sleep disruption in Parkinson’s disease. J Parkinson’s Dis. 2020;10:1467–1476. doi: 10.3233/JPD-202178.
    1. Park JC, Moura AL, Raza AS, Rhee DW, Kardon RH, Hood DC. Toward a clinical protocol for assessing rod, cone, and melanopsin contributions to the human pupil response. Invest Ophthalmol Vis Sci. 2011;52:6624–6635. doi: 10.1167/iovs.11-7586.
    1. La Morgia C, Romagnoli M, Pizza F, Biscarini F, Filardi M, Donadio V, et al. Chromatic pupillometry in isolated rapid eye movement sleep behavior disorder. Mov Disord. 2022;37:205–210. doi: 10.1002/mds.28809.
    1. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology. 2017;89:88–100. doi: 10.1212/WNL.0000000000004058.
    1. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30:1591–1601. doi: 10.1002/mds.26424.
    1. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71:670–676. doi: 10.1212/01.wnl.0000324625.00404.15.
    1. American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 5. Washington, DC: American Psychiatric Publishing, Inc.; 2013.
    1. Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, et al. MDS research criteria for prodromal Parkinson’s disease: MDS criteria for prodromal PD. Mov Disord. 2015;30:1600–1611. doi: 10.1002/mds.26431.
    1. Iranzo A, Stefani A, Serradell M, Martí MJ, Lomeña F, Mahlknecht P, et al. Characterization of patients with longstanding idiopathic REM sleep behavior disorder. Neurology. 2017;89:242–248. doi: 10.1212/WNL.0000000000004121.
    1. Postuma RB, Gagnon JF, Rompre S, Montplaisir JY. Severity of REM atonia loss in idiopathic REM sleep behavior disorder predicts Parkinson disease. Neurology. 2010;74:239–244. doi: 10.1212/WNL.0b013e3181ca0166.
    1. Yao C, Fereshtehnejad S-M, Dawson BK, Pelletier A, Gan-Or Z, Gagnon J-F, et al. Longstanding disease-free survival in idiopathic REM sleep behavior disorder: is neurodegeneration inevitable? Parkinsonism Relat Disord. 2018;54:99–102. doi: 10.1016/j.parkreldis.2018.04.010.
    1. Arnaldi D, Chincarini A, Hu MT, Sonka K, Boeve B, Miyamoto T, et al. Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder. Brain. 2021;144:278–287. doi: 10.1093/brain/awaa365.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere